^Iwata, H.; Naito, Y.; Hattori, M.; Yoshimura, A.; Yonemori, K.; Aizawa, M.; Mori, Y.; Yoshimitsu, J.; Umeyama, Y.; Mukohara, T. (November 2023). "58P Safety and pharmacokinetics (PK) of vepdegestrant in Japanese patients with estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Results from a Japanese phase I study". Annals of Oncology. 34: S1488–S1489.
doi:
10.1016/j.annonc.2023.10.193.
S2CID265657144.
^Iwata, H.; Hamilton, E.P.; Ma, C.X.; De Laurentiis, M.; Hurvitz, S.A.; Wander, S.A.; Danso, M.A.; Lu, D.R.; Perkins, J.; Liu, Y.; Tran, L.; Anderson, S.; Chappey, C.; Yang, D.Z.; Campone, M. (November 2023). "73TiP Global phase III studies evaluating vepdegestrant in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: VERITAC-2 and VERITAC-3". Annals of Oncology. 34: S1493.
doi:
10.1016/j.annonc.2023.10.207.
S2CID265654990.
^Iwata, H.; Naito, Y.; Hattori, M.; Yoshimura, A.; Yonemori, K.; Aizawa, M.; Mori, Y.; Yoshimitsu, J.; Umeyama, Y.; Mukohara, T. (November 2023). "58P Safety and pharmacokinetics (PK) of vepdegestrant in Japanese patients with estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Results from a Japanese phase I study". Annals of Oncology. 34: S1488–S1489.
doi:
10.1016/j.annonc.2023.10.193.
S2CID265657144.
^Iwata, H.; Hamilton, E.P.; Ma, C.X.; De Laurentiis, M.; Hurvitz, S.A.; Wander, S.A.; Danso, M.A.; Lu, D.R.; Perkins, J.; Liu, Y.; Tran, L.; Anderson, S.; Chappey, C.; Yang, D.Z.; Campone, M. (November 2023). "73TiP Global phase III studies evaluating vepdegestrant in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: VERITAC-2 and VERITAC-3". Annals of Oncology. 34: S1493.
doi:
10.1016/j.annonc.2023.10.207.
S2CID265654990.